Navigation Links
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
Date:8/21/2014

ilia patients. Baxter has the broadest portfolio of hemophilia treatments in the industry and is able to meet individual therapy choices, providing a range of options at each treatment stage. The company's work focuses on optimizing hemophilia care and improving the lives of people worldwide living with bleeding disorders.

About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements concerning BAX 855 and related clinical studies, including expectations with regard to regulatory filings. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; additional clinical results; changes in laws and regulations; product quality or supply or patient safety issues; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.


'/>"/>
SOURCE Nektar Therapeutics; Baxter International Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
2. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
3. FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard
4. Early Morning Insight: Baxter, CareFusion, Unilife, and Mindray Medical
5. Israeli Medical Device Company FlowSense Acquired by Baxter
6. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
7. United States Regenerative Medicine Market Analysis to 2016 Featuring Baxter, Medtronic, Stryker & Zimmer
8. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
9. Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific
10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... in bone mineral density at the,lumbar spine and ... salmeterol inhalation powder) and salmeterol, - Study ... in patients,with COPD, PHILADELPHIA, Oct. 29 ... three-year study of patients with,Chronic Obstructive Pulmonary Disease ...
... Cryoablation ... Treatment Technology, PLEASANTON, ... (ACOSOG) which just initiated a National Cancer,Institute (NCI) funded clinical ... Therapy in the Treatment of Invasive Breast,Carcinoma," has selected the ...
Cached Medicine Technology:Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 2Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 3NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3
(Date:12/24/2014)... For chic ladies, new fashionable outfits are necessary ... their Holiday Wish List, Angeldress.co.uk has chosen some ... accent ladies’ holiday wardrobe by launching a promotion on its ... the discount of 80% off, like a cheap suit. , ... company’s chic wedding dresses are among the hottest items in ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... regards to the various market dynamics such as the ... assisted arthroscopy, the wait time for U.S. sports medicine, ... medicine market, and the challenges faced by the market. ... http://www.researchmoz.us/global-sports-medicine-market-report-2014-edition-report.html , The report also provides an overview ...
(Date:12/24/2014)... Plantation, FL (PRWEB) December 24, 2014 ... permanent solution for a tooth replacement. They offer the ... boast several advantages over other forms of tooth replacement. ... not rely on the adjacent teeth for support, and ... many people have been told that they are not ...
(Date:12/24/2014)... Viejo, California (PRWEB) December 24, 2014 ... release of the ProDenoise from Pixel Film Studios. , “The ... noise or grain in their footage,” said Christina Austin, CEO ... have in any Final Cut Pro X editors toolbox.” , ... film noise or grain in their footage with ProDenoise from ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... good news about the experimental Ebola vaccine that U.S. officials ... shows a precursor of that vaccine produced a safe ... of the vaccine, when given to more than 100 Ugandans ... white blood cells that could potentially protect a person against ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
... Amanda Gardner HealthDay Reporter , TUESDAY, April ... the middle ground with its new drug control policy, ... Tuesday, rejects both the harsh "war on drugs" ... the push to legalize illegal drugs. Gil Kerlikowske, ...
... HOUSTON - Scientists who developed a technology for identifying and ... have found a way to penetrate the outer membrane and ... the cell. In a paper published today online in ... The University of Texas MD Anderson Cancer Center reports packaging ...
... , TUESDAY, April 17 (HealthDay News) -- The ... apparently because of changes in the brain,s white matter, a ... aged 21 to 85, to perform a learning task involving ... that age-related declines in decision-making are associated with the weakening ...
... , TUESDAY, April 17 (HealthDay News) -- ... reduce the spread of the AIDS-causing virus, but would ... high risk for HIV infection, according to a new ... to analyze the use of the combination drug tenofovir-emtricitabine ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, April ... patients, own tumor cells led to a nearly 50 percent ... the same malignancy that claimed the life of U.S. Sen. ... multicenter trial of about 40 patients with recurrent glioblastoma -- ...
... bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell ... in 2006 did not lead to significantly increase survival ... Medicare, a new study by Dana-Farber Cancer Institute researchers has ... 18 Journal of the American Medical Association , a ...
Cached Medicine News:Health News:White House Drug Policy Shifts Strategy 2Health News:White House Drug Policy Shifts Strategy 3Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 2Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 3Health News:HIV Prevention Pill Cost-Effective for High-Risk Men: Study 2Health News:Brain Tumor Vaccine Shows Promise in Early Trial 2Health News:Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients 2
... The SkanWasher 400 is ... microplate washer with built-in ... The individual pressure settings ... very gentle wash to ...
Lab-Reader...
Fully automatic NRTL and CE certified microplate reader....
... a compact and versatile multilabel ... design allows up to six ... counting, luminescence, absorbance, and fluorescence ... and fluorescence polarization all on ...
Medicine Products: